openPR Logo
Press release

Lawsuit filed for Investors in shares of Lipocine Inc. (NASDAQ: LPCN)

12-02-2019 06:53 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Lipocine Inc. (NASDAQ: LPCN) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Lipocine Inc. (NASDAQ: LPCN) shares over alleged securities laws violations.

An investor, who purchased NASDAQ: LPCN shares , filed a lawsuit over alleged violations of Federal Securities Laws by Lipocine Inc.

Investors who purchased shares of Lipocine Inc. (NASDAQ: LPCN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 14, 2020. NASDAQ: LPCN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Salt Lake City, UT based Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs.

Lipocine Inc’s lead product candidate is TLANDO (LPCN 1021), an oral testosterone replacement therapy. The Company has previously submitted New Drug Applications (“NDA”) for TLANDO twice and, both times, received Complete Response Letters (“CRL”) from the U.S. Food and Drug Administration (“FDA”) rejecting the NDAs. The Company received the first CRL in June 2016 and the second in May 2018.
On March 27, 2019, during pre-market hours, Lipocine Inc announced new topline results from a study evaluating TLANDO’s effects on blood pressure (one issue cited by the FDA in a prior CRL rejecting TLANDO’s NDA), as well as the Company’s intention to refile the NDA for TLANDO in the second quarter of 2019 (the “March 2019 Press Release”).
On November 11, 2019, Lipocine Inc announced the receipt of a CRL from the FDA regarding its NDA for TLANDO. In the press release, Lipocine advised investors that the FDA had again rejected the NDA for TLANDO—this time because an efficacy trial had not met three of its secondary endpoints.

Shares of Lipocine Inc (NASDAQ: LPCN) declined from $3.21 per share in October 2019 to as low as $0.38 per share on November 14, 2019.

The plaintiff claims that between March 27, 2019, and November 8, 2019, the defendants made false and/or misleading statements and/or failed to disclose that the results from Lipocine’s clinical studies of TLANDO were insufficient to demonstrate the drug’s efficacy, that accordingly, Lipocine’s third NDA for TLANDO was highly likely to be found deficient by the FDA, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Lipocine Inc. (NASDAQ: LPCN) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Lipocine Inc. (NASDAQ: LPCN) here

News-ID: 1874797 • Views: 184

More Releases from Shareholders Foundation

Lawsuit filed for Investors in Energy Transfer LP (NYSE: ET) over alleged Mislea …
An investor in Energy Transfer LP (NYSE: ET) filed a lawsuit over alleged violations of Federal Securities Laws by Energy Transfer LP in connection with certain allegedly false and misleading statements. Investors who purchased units of Energy Transfer LP (NYSE: ET) have certain options and for certain investors are short and strict deadlines running. Deadline: January 20, 2020. NYSE: ET investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors in shares of CBL & Associates Properties, …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at CBL & Associates Properties, Inc. Investors who purchased shares of CBL & Associates Properties, Inc (NYSE: CBL) and currently hold any of those NYSE: CBL shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CBL & Associates Properties
Lawsuit filed for Investors in shares of Aurora Cannabis Inc. (NYSE: ACB)
The Shareholders Foundation announced that an investor, who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), filed a lawsuit over alleged violations of Federal Securities Laws by Aurora Cannabis Inc. Investors who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), have certain options and for certain investors are short and strict deadlines running. Deadline: January 21, 2020. NYSE: ACB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Verb Technology Com …
An investigation on behalf of current long-term investors in shares of Verb Technology Company, Inc. (NASDAQ: VERB) concerning potential breaches of fiduciary duties by certain directors and officers of Verb Technology Company, Inc. was announced. Investors who are current long term investors in Verb Technology Company, Inc. (NASDAQ: VERB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a

All 5 Releases


More Releases for Lipocine

Trending Report : Male Hypogonadism Market Is Estimated To Reach $3,350 Million …
Male hypogonadism is a condition in which the body does not produce enough testosterone - a hormone that plays a key role in male growth and development during puberty - or has poor sperm production capacity or both .Male Hypogonadism Market Is Estimated To Reach $3,233 Million From $2,594 Million And Is Supported By a CAGR Of 3% During The Forecast Period Get Sample @ https://www.researchreportsinc.com/sample-request?id=31794 List of Key Players
Future of Female Contraceptive Products Market – A comprehensive study by Key …
MarketResearchNest.com adds “Global Female Contraceptive Products Industry Market Research Report” new report to its research database. The report spread across 103 pages with multiple tables and figures in it. This report studies the Female Contraceptive Products market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers.
New Report on : Global Topical Contraceptive Market 2017-2021 ; Analysis and Key …
Researchmoz added Most up-to-date research on "Global Topical Contraceptive Market 2017-2021" to its huge collection of research reports. About Topical Contraceptive Topical contraceptives are contraceptive patches that release hormones, estrogen, and progestin to prevent pregnancies. They work in a similar manner as oral contraceptives. Various temporary and permanent contraceptive methods and devices for women are available in the market. Permanent methods such as sterilization are considered the most effective as they
Global Premature Labor Treatment Market Size 2018-2023 ObsEva, Lipocine, AMAG Ph …
A market study "Global Premature Labor Treatment Market" examines the performance of the Premature Labor Treatment market 2018. It encloses an in-depth Research of the Premature Labor Treatment market state and the competitive landscape globally. This report analyzes the potential of Premature Labor Treatment market in the present and the future prospects from various angles in detail. The Global Premature Labor Treatment Market 2018 report includes Premature Labor Treatment market Revenue,
At a CAGR of 2%, Global Topical Contraceptive Market to rise over Forecast perio …
Topical contraceptives are contraceptive patches that release hormones, estrogen, and progestin to prevent pregnancies. They work in a similar manner as oral contraceptives. Various temporary and permanent contraceptive methods and devices for women are available in the market. Permanent methods such as sterilization are considered the most effective as they eliminate the chances of pregnancy. The global topical contraceptive market to grow at a CAGR of 2% during the period 2017-2021.
Global Womens Health Market 2016-2020 - Allergan, Bayer HealthCare, Merck, Pfize …
Womens health refers to the overall well-being experienced by women this includes physical, mental, and social well-being. It deals with the diagnosis and treatment of various diseases and conditions that affect women such as HIV/AIDS, endometriosis, infertility, polycystic ovary syndrome, postmenopausal osteoporosis, and cancer (primarily ovarian and breast cancer). It also includes issues other than the biological conditions, like gender inequality (women are sometimes not able to afford medical treatments)